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Cachexiaisamultifactorialprocessofskeletalmuscleandadiposetissueatrophyresultinginprogressiveweightloss.Itisassociated
withpoorqualityoflife,poorphysicalfunction,andpoor prognosisincancerpatients.It involvesmultiplepathways:procachectic
and proinﬂammatorysignalsfrom tumour cells, systemicinﬂammationin the host,and widespread metabolic changes (increased
resting energy expenditure and alterations in metabolism of protein, fat, and carbohydrate). Whether it is primarily driven by the
tumour or as a result of the host response to the tumour has yet to be fully elucidated. Cachexia is compounded by anorexia and
therelationshipbetween thesetwo entities hasnot been clariﬁedfully. Inconsistenciesin thedeﬁnitionof cachexia havelimited the
epidemiological characterisation of the condition and there has been slow progress in identifying therapeutic agents and trialling
them in the clinical setting. Understanding the complex interplay oftumour and hostfactors will uncover new therapeutic targets.
1.Introduction
The etymology of the word cachexia points to its association
with poor prognosis: it is derived from the Greek kakos and
hexia—“bad condition” and has long been recognised as a
key sign in many cancers. It is a multifactorial condition
which comprises skeletal muscle and adipose tissue loss
which may be compounded by anorexia, a dysregulated
metabolic state with increased basal energy expenditure
and is resistant to conventional nutritional support. The
pathophysiological mechanisms have begun to be elucidated
and this has led to developmentsin therapeutic avenues [1].
Cachexia correlates with poor performance status, poor
quality of life, and a high mortality rate in cancer patients
[2]. In a meta-analysis of studies pertaining to patients
with advanced cancer and survival of less than 90 days,
symptomsincludingweightlossandanorexiacorrelatedwith
poor prognosis [3]. Loss of greater than 5–10% of body
weight is usually taken as a deﬁning point for cachexia,
although the physiological changes may be present long
before this cutoﬀ point is reached. Furthermore, the degree
of weight loss which signiﬁcantly impacts on prognosis or
performance has not been deﬁned. A longitudinal study has
shown that 2.5kg weight change over 6–8 weeks is suﬃ-
cient to produce signiﬁcant changes in performance status
[4]. Death usually occurs when there is 30% weight loss
[5].
The prominent clinical feature of cachexia is weight loss
in adults (corrected for ﬂuid retention) or growth failure in
children (excluding endocrine disorders). Anorexia, inﬂam-
mation, insulin resistance, and increased muscle protein
breakdown are frequently associated with cachexia [6].
However, there is no clear consensus deﬁnition of this
common problem in cancer patients leading to a poor
understanding of the aetiology of the condition. Earlier
deﬁnitions of cachexia described “a wasting syndrome
involving loss of muscle and fat directly caused by tumour
factors, or indirectly caused by an aberrant host response
to tumour presence” [7], however more recent deﬁnitions
have downplayed the importance of fat loss and describe
cachexia as “a complex metabolic syndrome associated with
underlying illness and characterised by loss of muscle with
or without loss of fat mass” [6], thus highlighting the unique
consequences of muscle wasting—the hallmark of cachexia.
Without an established deﬁnition, future studies in this area
will be hampered. A recent consensus deﬁnition has been
proposed to include further factors to diagnose the cachexia
syndrome such as involuntary weight loss, decreased muscle
mass, anorexia, and biochemical alterations (C-Reactive
Protein (CRP), albumin, haemoglobin [8]).2 Gastroenterology Research and Practice
One such study looked at 170 pancreatic cancer patients
with weight loss >5% and whether a triad of >10%
weight loss, low food intake (<1500kcal/day), and systemic
inﬂammation (CRP>10mg/dL)couldbetterpredictadverse
functional outcome as well as poor prognosis versus weight
loss alone [8]. When two of three of these criteria were
present, (representing 60% of the patients) a cohort of
patients with adverse function and prognosis were identiﬁed
[8].
The prevalence of cachexia is thought to be up to 80%
of upper gastrointestinal cancer patients and 60% of lung
cancer patients at the time of diagnosis [9]. There are no
clear ﬁgures for the estimated prevalence within speciﬁc
cancer cohorts. When the electronic medical records of
over 8500 patients with a wide variety of malignancies
were analysed for the prevalence of cachexia amongst the
cohort, the proportion varied according to which standard
deﬁnition was used: 2.4% using the World Health Organisa-
tion’s International Classiﬁcation of Diseases (ICD) cachexia
diagnostic code; 5.5% for the ICD diagnosis of cachexia,
anorexia, abnormal weight, and feeding diﬃculties; 6.4%
were prescribedmegestrol acetate,oxandrolone, somatropin,
or dronabinol; 14.7% had >5% weight loss [10]. Despite
methodologicalﬂaws, therewasaninteresting lackofoverlap
between the diﬀerent criteria pointing to the underdiagnosis
of cachexia in clinical practice.
Decreased musclestrength may help distinguish cachexia
from other causes of anorexia and fatigue in cancer patients
[11].Decreasedmusclestrengthcouldbeusedasadiagnostic
criterion with greater sensitivity and speciﬁcity for cancer
cachexia. Cancer patients who are losing weight and have
a systemic inﬂammatory response have poorer performance
status [4]. Until a clear deﬁnition with well-deﬁned cut-oﬀs
emerges, identiﬁcation and treatment of cachectic patients
as well as research in the area will remain limited. A
new consensus deﬁnition for diagnostic purposes has been
suggested and is outlined in Table 1 [6].
2.Pathophysiology
Pathophysiological changes and clinical consequences of
cachexia are summarised in Figure 1.
2.1. Metabolic Changes. The metabolic changes found in
cachexia resemble those of infection rather than starvation
[12] and are multifactorial and complex. Weight loss of
cancer cachexia is due to loss of both skeletal muscle
and adipose tissue mass, whereas weight loss is mainly
from adipose tissue stores in starvation [13]. In cachexia
there is an increase in muscle protein catabolism leading
to net loss of muscle mass. The ATP ubiquitin-dependent
proteolytic pathway is the greatest contributor to proteolysis
in cachexia [14, 15] .O t h e rp r o t e o l y t i cp a t h w a y ss u c ha s
l y s o s o m a lc a t h e p s i n sB ,H ,D ,a n dL[ 16]a n da c t i v i t yo f
the calcium/calpain pathway have also been implicated [17].
Increased intracellular proteolytic activity usually manifests
as loss of body weight. This proteolysis has been shown to
occur even in the absence of weight loss in cancer patients.
Activation of proteolysis is an early event during tumour
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Figure 1: Clinical consequences of cancer cachexia.
growth and it may be present for a long time prior to its
clinical manifestation. Protein synthesis may be increased or
unchanged [18].
Loss of adipose tissue mass is due to lipolysis [5]. This
process is driven by lipid mobilising factor (LMF) and
tumour (and host) factor zinc-alpha-2 glycoprotein which
has adirect lipolyticeﬀectand sensitises adipocytestolipoly-
tic stimuli and shows increased expression in cachexia [19].
Afurther compounding factoris theincreased resting energy
expenditure due to the dysregulation of energy metabolism.
Cancer patients have a higher resting energy expenditure
than noncancer controls[20].Ithasbeen speculatedthatthis
isduetoaltered geneexpression ofmitochondrial membrane
uncoupling proteins which uncouple respiration from ATP
production resulting in loss of energy as heat [5].
The metabolic changes seen in cachexia are a result ofthe
interplay of tumour factors, host factors, and the interaction
between the two.
2.2. Tumour Factors. Tumour cells produce both pro-
inﬂammatory and procachectic factors, which stimulateGastroenterology Research and Practice 3
Table 1: Diagnostic criteria for cachexia syndrome [6].
Weight loss of at least 5% in 12 months or less
(or BMI <20kg/m2)
AND 3 of 5 From:
Decreased muscle strength
Fatigue
Anorexia
Low fat-free mass index
Abnormal biochemistry:
Increased inﬂammatorymarkers (CRP, IL-6)
Anaemia (Hb < 12g/dL)
Low serum albumin (<3.2g/dL)
Note: Fatigue is deﬁned as physical and or mental weariness resulting from exertion; an inability to continue exercise at the same intensity with a resultant
deterioration in performance.
Anorexia is deﬁned as limited food intake (total caloric intake less than 20kcal/kg body weight/day) or poor appetite.
Low-fat-free mass index represents lean tissue depletion (i.e., mid upper arm muscle circumference <10th percentile for age and gender’ appendicle skeletal
muscleindex by DEXA <5.45 (kg/m2) in females and <7.25 in males).
a host inﬂammatory response [1]. Tumour produced pro-
cachectic factors include proteolysis-inducing [45]a n d
Lipid-mobilising factors [46]. PIF has been identiﬁed in
the urine of weight losing patients with pancreatic, colon,
lung, ovarian, breast, and liver cancers [47]. In animals,
PIF signals via NFκBa n dS T A T 3p a t h w a y s[ 48]. Stimulation
of these pathways, induces proteolysis in muscles via the
ubiquitin-proteasome pathway [49] and in hepatocytes,
results in production of IL-6, IL-8 and CRP [48]. Tumour
xenografts expressing human PIF do not induce cachexia
in mice [50]. Further attempts to correlate PIF levels and
outcomes have not shown any correlation [51]. Therefore
the proposed mechanisms of PIF have not yet been validated
in humans. Parathyroid hormone-related peptide (PTHrP),
another tumour-derived circulating factor, is associated with
higher soluble tumour necrosis factor receptor levels and
with lower albumin and transferrin levels [52].
Lipid mobilising factor has been found in cancer patients
losing weight but not in those with stable weight [53]. It is
thought that LMF sensitises adipocytes to lipolytic stimuli
by increasing cyclic AMP production [54]. LMF may bind
to beta adrenergic receptors and causes either increased
receptor number or increased G protein expression [55].
2.3. Host-Tumour Interaction. Inﬂammatory cytokine pro-
duction by the tumour microenvironment in response
to tumour cells may drive the cachexia process. Rodent
tumour models display increased systemic inﬂammatory
cytokine production, which correlates with the amount of
weight loss [56, 57] .T h em u r i n em o d e lo fc a n c e rc a c h e x i a
associated with systemic inﬂammation suggests that there
is an interplay between IL-1β and IL-6 within the tumour
microenvironment, which leads to their ampliﬁcation [58].
Reduction of IFN-γ by monoclonal antibody treatment
reverses cachexia in the Lewis lung carcinoma in mice [59].
Pro-inﬂammatory cytokines produced include TNF-α,
IL-1 and IL-6 [1]. It is not certain whether the cytokine pro-
ductionisprimarilyfromtumourorhostinﬂammatory cells.
It has been hypothesised that either tumour cell production
of pro-inﬂammatory cytokines or the host inﬂammatory
cell response to tumour cells is the source of the acute
phase protein response seen in many malignancies and in
cachexia. One study of oesophagogastric cancers showed
cytokine protein concentrations of IL-1β,I L - 6a n dT N F - α
are signiﬁcantly elevated in tumour tissue. Tumour tissue
concentrations of IL-1β protein correlated with serum CRP
concentrations (r = 0.31, P = .05; linear regression) and
tumours with diﬀuse or patchy inﬂammatory cellular inﬁl-
tratewereassociatedwithelevatedserumCRP[60].Similarly
the production of IL-6 by Peripheral Blood Mononuclear
Cells (PBMCs) in pancreatic cancer patients induced an
acute phase protein response in another study [61]. Mar-
tignoni et al. have suggested that IL-6-overexpression in
cachectic pancreatic cancerpatientsis related to the ability of
IL-6 producing tumours to sensitise PBMC and induce IL-6
expression in PBMCs [62].
TNF-alpha and the tumour factor proteolysis-inducing
factor are the major contenders for skeletal muscle atrophy
in cachectic patient. They both increase protein degradation
through the ubiquitin-proteasome pathway and depress
protein synthesis through phosphorylation of eukaryotic
initiation factor 2 alpha [19]. Studies have shown that
proteolysis-inducing factor levels correlate with the appear-
ance of cachexia, but there is some disagreement regarding
a correlation between serum levels of TNF-alpha and weight
loss. Furthermore, only antagonists to proteolysis-inducing
factor prevent muscle loss in cancer patients, suggesting that
tumour factors are the most important.
2.4. Host Response Factors
2.4.1. Acute Phase Protein Response. Systemic changes in
response to inﬂammation are denoted the acute phase
response [63]. Up to 50% of patients with solid epithe-
lial cancers may have an elevated acute phase protein
response [64]. This acutephase protein response (APPR) has
been associated with hypermetabolism: in pancreatic cancer
patientsAPPRcorrelatedwith elevatedresting energyexpen-
diture and reduced energy intake [65]. Other longitudinal
studies have found a poorer prognosis in patients displaying
this response, independent of weight loss [66]. C-reactive
protein (CRP) is the most prevalent method used to assess4 Gastroenterology Research and Practice
Table 2: Modiﬁed Glasgow Prognostic Score (mGPS): an inﬂam-
mation-based prognostic score [21].
Biochemical measure Score
C-reactive protein ≤10mg/L + Albumin ≥35g/L 0
C-reactive protein ≤10mg/L + Albumin <35g/L 0
C-reactive protein >10mg/L 1
C-reactive protein >10mg/L + Albumin <35g/L 2
the magnitude of the systemic inﬂammatory response [63].
The modiﬁed Glasgow prognostic score (mGPS) (Table 2)
combines CRP and albumin concentrations to create a sim-
ple scoring system which is a prognostic factor independent
of stage and treatment and predicts survival [21, 67].
Raised CRP concentrations at the time of admission
to hospital are indicative of an increased risk for all-cause
mortality; there is a 22.8-fold increase in cancer mortal-
ity in patients with highly elevated CRP concentrations
(>80mg/L) [68]. This response appears to be prevalent
amongst cancer patients with elevated CRP measured in
almost 80% of 106 patients with inoperable nonsmall cell
lung cancer (NSCLC), 40% of whom had >5% weight loss
[69]. In patients without weight loss, those who displayed
evidenceof a systemic inﬂammatory response reported more
fatigue (P<. 05) [69]. In patients with gastro-oesophageal
cancer, the rate of weight loss correlates with serum con-
centrations of C-reactive protein [70]. Elevated CRP levels
at the time of diagnosis has been found to be a predictor
of poor prognosis in pancreatic, lung, melanoma, multiple
myeloma, lymphoma, ovarian, renal, and gastrointestinal
tumours [71].
The exact mechanisms linking cachexia, APPR, and
poor outcomes is not known. It may be that this systemic
alteration in protein metabolism drives the proteolysis of
skeletal muscle to fuel the switch to acute phase reactant
production. The APPR requires large amounts of essential
amino acids: 2.6g of muscle protein must be catabolised to
produce 1g of ﬁbrinogen [72].
2.4.2. Neuroendocrine Factors. A number of neuroendocrine
factors appear to be dysregulated in the cancer state resulting
in insulin resistance, reduced anabolic activity, and elevated
cortisol [47]. This dysregulation may be driven by the
systemic inﬂammatory response associated with cancer.
Inﬂammatory cytokines such as TNF-α and IL-6 have been
implicated in insulin resistance [73]. The endogenous pro-
duction of or response to anabolic growth factors in patients
may be aﬀected either by the tumour or the host response to
the tumour and may contribute to cachexia. Testosterone or
derivativeshavebeenshowntoincreaseproteinsynthesis and
musclemass[74].Emergingevidenceimplicatesreductionin
insulin-like growth factor 1 in cachectic states [75].
2.5. Anorexia and Cachexia: An Interdependent Relationship?
Whilstlossofappetiteandresultantdecreaseinenergyintake
undoubtedlycontributetoweight loss associated with cancer
cachexia,whetheranorexiaoccursbyanindependentprocess
or is a result of the inﬂammatory process of cachexia is
not fully understood. Anorexia itself may have a number
of components—nausea, altered taste sensation, swallowing
diﬃculties, or depression. The failure of aggressive supple-
mentary nutritional regimes to reverse weight loss in many
patients points to primacy of the cachexia disease process [5]
and in fact, this disease process may act to establish anorexia.
It is thought that lack of appetite is secondary to factors
produced by the tumour or the immune response to the
tumour. Speciﬁcally, cytokines may inhibit the neuropeptide
Ypathwayormimic negative feedbackactionofleptinonthe
hypothalamus, leading to anorexia [76, 77].
In a study of patients with gastro-oesophageal malig-
nancy (n = 220), 83% of whom had weight loss, multiple
regression identiﬁed dietary intake (estimate of eﬀect: 38%),
serum CRP concentration (estimate of eﬀect: 34%), and
stage of disease (estimate of eﬀect: 28%) as independent
variables in weight loss in these patients [70]. If serum CRP
is taken as a proxy measure of systemic inﬂammation due to
cancer cachexia, this indicates that weight loss in cancer is
not merely due to reduced calorie intake.
Recently,understandingofthephysiologicalmechanisms
of appetite regulation has been increasing. There are two sets
of neurons within the arcuate nucleus of the hypothalamus
identiﬁed to be involved: the melanocortin system and
the neuropeptide Y system. Neuropeptide Y stimulates
appetite on its own or via release of other orexigenic pro-
teins [78]. Neurons which release α-melanocyte-stimulating
hormone (α-MSH) and signal via melanocortin-3 and 4
receptors (MC3R, MC4R) result in decrease in food-seeking
behaviour, increased basal metabolic rate and decreased
lean body mass [79, 80]. These neurons are constitutively
active as mutation in the MC4R results in childhood obesity
[81]. Agouti-related protein (AgRP) is produced by neurons
(which also produce neuropeptide Y) and counteracts the
action of MC4R-stimulating proteins promoting appetite
[82]. These “appetite neurons” also express receptors for
circulating leptin [83] and interleukin-1β (IL-1β)[ 84], both
of which downregulate appetite and receptors for ghrelin
(the orexigenic protein, which increases AgRP) [85].
3.Consequences
Cachexia results in a state of active inﬂammation whereby
tumour-derived factors and the aberrant host response
to these factors result in a catabolic state. Whether this
catabolic state is the ultimate cause of death in some
patients is unknown although a substantial proportion of
cancer patients die with symptoms of advanced cachexia [9].
Cachexia directly impacts overall survival, quality of life, and
physical activity.
3.1.Survival. Weightlosshasbeenindicatedasan important
prognostic factor for cancer patients. A classic study by
DeWys and colleagues underscores the impact and outcome
of weight loss in cancer patients [2]. Using retrospective
evaluation in a multicentre study of more than 3000 patients
with diﬀerent tumour types, these researchers reported
moderate to severe weight loss in 30% to 70% of patients,
depending on the tumor type. The amount of weight lossGastroenterology Research and Practice 5
depends upon tumor site, size, type, and stage. Age and
treatment type also play a role. The greatest incidence of
weight loss was seen among patients with solid tumours, for
example, gastric, pancreatic, lung, colorectal, and head and
neck.Patients with solid tumoursare often likely to lose 10%
or more of their usual body weight. There is a lower risk of
weightlossinpatientswithbreastandhematologicalcancers.
Within each tumour type, survival times were shorter for
patients who had experienced weight loss than in those who
did not. Not only did weight loss predict overall survival,
but it also indicated a trend towards lower chemotherapy
response rates.
In more recent studies, similar ﬁndings of reduced
survival have been reported. Buccheri and Ferrigno (2001)
[86] reported in 388 NSCLC cases that total weight loss was
the best indicator of prognosis. In ovarian cancer Hess et al.
(2007) [87] found a signiﬁcant relationship between weight
change and survival—on multivariate analysis the risk of
death increased by 7% for each 5% drop of body weight. In
Gastro-oesophageal cancer Deans and Wigmore (2009) [71]
reported that patients with the lowest rate of weight loss had
a median survival of 30.2 months versus 7.5 months in those
withthehighest rateofweight loss. Similarﬁndings havealso
been reported in pancreatic cancer [88].
One proposed mechanism to explain why patients
with weight loss have a poorer survival is the increased
incidence of complications from surgical, radiotherapeutic,
and chemotherapeutic treatments. In a study by Andreyev
et al. [89], 1555 patients with a number of diﬀerent
gastrointestinal tumour types were analysed to examine
whether weight loss aﬀected prognosis. In patients with
weight loss: chemotherapy doses were lower; they developed
more frequent and more severe dose limiting toxicity and
received, on average, one month less chemotherapy (P<
.001 in all). Weight loss correlated with shorter failure-free
survival, overall survival, decreased response, quality of life,
and performance status (P<. 001 in all) [89]. Whether
reduced survival is due to a more aggressive tumour proﬁle
in patients with weight loss or due to suboptimal treatment
related to weight loss, remains unknown.
3.2. Quality of Life. Cachexia contributes substantially to
morbidity in cancer patients. It is associated with symptoms
such as fatigue, weakness, poor physical performance, and
thus leads to a lower self-rated quality of life. Indeed, when
the impact of various factors is related to self-rated quality
of life scores, the proportion determined by weight loss is
30% and by nutritional intake 20%, compared to cancer
location (30%), disease duration (3%), and stage (1%)
[90]. Patients who continue to lose weight while receiving
palliative chemotherapy have reduced global quality of life
and performance scores when compared to those whose
weight loss stabilises [91].
3.3. Physical Activity. Physical activity has been described
as a novel, objective, and robust functional outcome mea-
sure that is frequently impaired in cachectic states [92].
Activity levels are inﬂuenced by several conventional quality
of life domains. Measurement of physical activity has
long represented a challenge for researchers using time-
consuming and expensive tools such as doubly labelled
water and indirect calorimetry. However research using
these methods has revealed that although resting energy
expenditure may be elevated in cachectic patients, total
energy expenditure is reduced because weight-losing cancer
patientsreducethe magnitudeoftheirenergydeﬁcitthrough
reductions in physical activity. This reduction in physical
activity can be signiﬁcant—in one study the measured mean
physical activity rate was equivalent to that of spinal cord
injury patients living at home and greatly reduced versus
normal controls [93]. In a more recent study by Dahele
et al. (2007) [94] using advanced ambulatory pedometer
technology, cancer patients receiving palliative chemother-
apy were shown to spend signiﬁcantly more time lying
and sitting, and signiﬁcantly less time in quiet standing
or stepping compared with controls, taking on average
43% less steps than healthy controls. It is known that bed
rest leads to a decrease in skeletal muscle mass in healthy
patients, due to reduced protein synthesis [95]. Thus, loss of
physical function results in decreases in performance status,
ability to perform activities of daily living, decreased social
interactions, and alterations in body image, all of which
manifest as reduced quality of life [96]. Interventions which
increase physical activity would be anticipated to be highly
beneﬁcial.
Antineoplastic therapies such as surgery, radiotherapy
and chemotherapy, may also impact on the development
of systemic inﬂammation and particularly may impact on
swallowing diﬃculties and anorexia due to nausea [97].
4.TherapeuticApproaches
4.1. Goals of Therapy. Clearly since cancer cachexia is
associated with a poor prognosis, the aim of management is
often to improve symptoms and quality of life. It is noted
that a response to chemotherapeutic treatment by shrinkage
of the tumour burden often leads to improvement in the
cachectic state. The primary endpoints of optimal treatment
of cancer cachexia are improvements in lean body mass,
resting energy expenditure, fatigue, anorexia, quality of life,
performance status, and a reduction in pro-inﬂammatory
cytokines.
A greater understanding of the process of inﬂammation
and its fundamental role in the development of cachexia
has led to new avenues opening up in the approach to
management of the condition. The hypothesis is that eﬀec-
tive treatment of cancer cachexia will improve performance
status and quality of life and by inhibiting the process
driving cachexia, survival may be improved. In patients
who stop losing weight while receiving chemotherapy for
gastrointestinal cancers, median survival is improved (15.7
months versus 8.1 months, P = .0004) [89]. Animal models
are generally unsatisfactory models for assessing the eﬃcacy
of intervention due to the larger proportional size and the
aggressive doubling rate of tumours: thus the biological
behaviour is diﬀerent to that seen in the clinical setting [98].
Therehasbeenrecentprogressinproducingtrialsofhigh
clinical quality for licensing purposes but these trials may6 Gastroenterology Research and Practice
Table 3: Endpoints for evaluating interventions in cancer cachexia.
Clinical Functional Biochemical
Nutritional status Performance score (ECOG; Karnofsky) Plasma fatty acid composition
Tolerance of diet Quality of life scores Pro-inﬂammatorycytokines
GI symptoms Appetite Acute phase protein reactants
Infections Fatigue
Survival Physical activity as measured electronically [22]
Muscle strength
be beset by diﬃculties in adequate endpoint analysis due to
the numbers lost to followup or patients being unable to
complywiththerapyduetotheirpooroverallcondition,thus
limiting their duration, power, or generalisability [99, 100].
In addition there is a degree of heterogeneity in deﬁning
relevant end points for analysis of intervention in cancer
cachexia. Table 3 summarises the range of endpoints which
may be used. One study of 388 nonsmall cell lung cancer
patients found that total weight loss was the best predictorof
prognosis rather than speed of weight loss [101]. However,
weight loss alone does not identify the full eﬀect of cachexia
on physical function [8]. It is the loss of fat-free mass
(FFM) that is responsible for the reduced functional status,
increased mortality, and other negative outcomes associated
with malnutrition [102]. Body fat is easier to gain than FFM,
so studiesthat show improved body weight may not translate
into reductions in morbidity or improvements in functional
status. To improve functional ability and hence quality of life
patientsneednotonlytobecomeweightstablebutregain the
lean tissue lost in the cachectic process. Thus, interventions
which lead to improvements in functional status would be
expected to cause increases in lean body mass rather than
fat mass, however, this distinction is often not reported in
interventions.
The strong impact that cancer cachexia has on cancer
patients’ outcome and quality of life suggests that nutritional
issuesshould betakeninto considerationfromthebeginning
ofthe natural history of cancer, a concepttermed the parallel
pathway [103]. Indeed studies of nutritional intervention
that have reported a better weight maintenance in patients
are in those who are treated in the “precachexia” phase,
that is, prior to loss of >10% of body weight and prior to
elevations of CRP. Dietary counselling with or without oral
nutritional supplements has proven eﬃcacy in stabilising
nutritional status in pre-cachectic patients [104, 105]. A
nutritional assessment to seek reversible causes of weight
loss is the ﬁrst step in management in cachectic patients.
Approximately 40% of cancer patients eat less than the
34kcal/kg/day required to maintain weight [106]. The Euro-
pean Society of Parenteral and Enteral Nutrition (ESPEN)
report in a consensus statement that there is Grade A
evidence for intensive dietary counselling with food plus or
minus oral nutritional supplements in preventing therapy-
associated weight loss, preventing treatment interruptions
and increasing dietary intake in gastrointestinal or head and
neck cancer patients undergoing radio- or chemotherapy
[107].
For patients with advanced cachexia (>10% weight loss,
systemic inﬂammation and poor appetite) studies seeking to
assess the eﬀect of targeted nutritional advice and supple-
ments have generally reported no signiﬁcant improvement
in nutritional status. Standard enteral or parenteral supple-
ments do not appear to result in lean mass weight gain for
the typical cancer patient [5, 98, 108]. The largest evaluation
of the literature regarding nutritional supplementation (NS)
(oral or tube) in cancer patients was the systematic review
by Elia et al. (2006) showing no diﬀerence in mortality in
patients undergoing chemotherapy/radiotherapy (4 RCTs)
or surgery (4 RCTs) [109]. A systematic review of par-
enteral nutrition in cancer patients showed no diﬀerence in
mortality (19 RCTs), increase in total complication rates in
those given parenteral nutrition (8 RCTs), and signiﬁcantly
lower tumour response rate in patients receiving parenteral
nutrition (15 RCTs) [110].
This is likely because the inﬂammatory response of
cachexia prevents anabolism. In many cases an attempt is
being made to reverse or halt a rapidly advancing catabolic
process and it is unrealistic to expect a reversal with calories
and protein alone.
The poor results observed with conventional nutrition
support in cachectic patients led to the emergence of so-
called nutraceuticals or immunonutrition supplements, in
an attempt to nutritionally modify the metabolic milieu by
providing anti-inﬂammatory substances, such as eicosapen-
taenoic acid (EPA), at levels much higher than that typically
found in the diet.
4.2. Eicosapentaenoic Acid. Eicosapentaenoic acid (EPA), a
long-chain polyunsaturated fatty acid (PUFA)ofthe omega-
3 (n-3) family, has been studies in relation to cancercachexia
for over 15 years. It is of interest in the context of cancer
cachexia as it has potential to impact on both the underlying
metabolic abnormalities of tumour-induced weight loss, as
well as modulation of immune function. When EPA is
consumed at levels above that normally found in the diet,
it replaces arachidonic acid (AA), an n-6 PUFA, in cell
membrane phospholipids. It then acts as a substrate for
the production of the 3 series prostaglandins and the 5
series leukotrienes. Eicosanoids synthesized from the n-3
PUFAs (i.e., EPA) rather than the n-6 PUFAs (i.e., AA) have
lower potential for promoting inﬂammation. Modulation
of dietary fatty acids can therefore have an impact on
many immune processes such as proliferation, phagocytosis,
cytotoxicity, and cytokine production [111].Gastroenterology Research and Practice 7
Table 4: Pharmacologicaloptions for managementof cachexia.
Agent Clinical eﬀect (RCT)# Hypothetical mechanism of action
Anabolic agents Corticosteroids
Improves anorexia and weakness;
no improvement in weight or
c a l o r i ei n t a k e[ 23–25]; well
tolerated; eﬀects short lasting
Not established. May inhibit
prostaglandin metabolism and
central euphoric eﬀect
Nandrolone decanoate Decrease in weight loss [26] Not established. Promote protein
nitrogen accumulation
Oxandrolone No published randomised clinical
trials in cancer cohort Not established
Insulin Increases whole body fat and
carbohydrate intake [27] Not established
Adenosine Triphosphate (ATP) Stabilises weight loss and increases
energy intake[28] Not established
Appetite stimulants Progesterones: Megestrol acetate (MA)
Medroxyprogesterone (MP)
Improves appetite, calorie intake
and weight (not lean body mass)
[29]
MA: may increase the central
appetite stimulant neuropeptide
YMP: reduces serotonin and
cytokine production by PBMCs
[30]
Cannabinoids:Dronabinol
No beneﬁt when added to MA;
inferior to MA when used alone
[31]. No increase in appetite or
QoL [32]
May act on endorphin receptors,
reduce prostaglandin synthesis or
inhibit IL-1 secretion [33]
Cytokine inhibitors Cyproheptadine No improvement in weight gain
[34]
Serotonin antagonistwith
antihistaminicproperties
Thalidomide Attenuates weight loss,increases
lean body mass [35]
Immunomodulatory:
downregulates TNF-α (by
destabilising mRNA [36]), NFκB,
pro-inﬂammatory cytokines,
COX2 [37]
Pentoxifylline No improvement in appetite or
weight in cachectic patients [38]
Phosphodiesterase inhibitor:
inhibits TNF gene transcription
Eicosapentaenoic acid (EPA)
Cochrane meta-analysis:
insuﬃcient evidence to establish
whether EPA is better than
placebo [39]
In vitro attenuates increased cAMP
activity and lipolysis by LMF [40]
Melatonin
Improves cachexia (term not
deﬁned) and one year survival
increased in advanced NCSC lung
cancer [41]
Immunomodulatory [42],
Downregulates TNF production
[43]
Anti-inﬂammatories Non-steroid anti-inﬂammatory drugs
Reduced inﬂammatorymarkers,
reduced resting energy
expenditure, preservation of total
body fat [44]
Not established. May
downregulate systemic
inﬂammatory response to tumour
#Results from randomised controlled trials (RCTs) are cited.
Despite initial studies showing anabolic eﬀects, princi-
pallygains ofleanbodymass, improvementsingripstrength,
quality of life, and reductions in IL-6 and PIF could be
achieved in a variety of cancers [99], including pancreatic
cancer [112, 113], lung cancer [114], and colorectal cancer
[115], analysis of RCTs only, using the Cochrane approach,
did not show any diﬀerences between EPA supplementation
and placebo [39]. Whether this is a true representation
or a reﬂection of the advanced cachexia of participants or
inherent diﬀerences in EPA metabolism between individuals
(with only a proportion of patients able to respond to
EPA) needs further examination. On subgroup analysis,
patients who comply with EPA supplementation seem to
have improved lean body mass [116].
EPA-enriched oral nutritional supplements (ONSs) have
been compared to megestrol acetate in the North Central
Cancer Treatment Group trial of 421 patients with weight
loss, poor intake, and anorexia [117]. In a 3-month inter-
vention period, patients were randomized to either EPA-
enriched ONS plus placebo liquid suspension, standard
ONS plus megestrol acetate suspension, or EPA-enriched
ONS plus megestrol acetate suspension. Weight gain was
highest in the megestrol acetate group but unfortunately
body composition was not assessed and so changes in water8 Gastroenterology Research and Practice
weight cannot be controlled for. There was no diﬀerence in
survival,appetite,orqualityoflifescoresbetweenthegroups,
however patients on megestrol acetate reported higher rates
of impotence. The fact that an EPA enriched ONS scored
as well as drug therapy on certain clinical endpoints (e.g.,
survivalandglobalqualityoflife)underscoresthelimitations
of each treatment.
β-hydroxyl β-methyl butyrate (HMB), glutamine, and
arginine supplementation have been combined in the hope
of a synergistic eﬀect of HMB (a modulator of protein
turnover) and the amino acids (immunomodulatory) would
increase weight. A phase III RCT ofthis combination did not
show any diﬀerence in lean body mass between control and
intervention groups [100].
4.3. Pharmacological Agents. Pharmacological options are
summarised in Table 4. Among orexigenic agents, megestrol
acetate is by far the most widely prescribed and at least 15
randomised controlled clinical trials have demonstrated that
this drug, at doses ranging from 160–1600mg/d signiﬁcantly
improves appetite with respect to placebo [118]. A recent
Cochrane meta-analysis reported that it improves weight
gain and appetite in cancer patients [29]. Although this
increase in appetite is very desirable for both patients and
theircarers, inmost ofthesetrials nodeﬁnitiveimprovement
in global quality of life was observed [29].
Anti-inﬂammatory agents (COX inhibitors) can reduce
weight loss and aid maintenance of performance status in
advanced cancer [119]. The COX-2 inhibitor, meloxicam
showed activity against PIF-induced proteolysis, prior to
its withdrawal from the market [120]. Beta-adrenoreceptor
blockade can reduce resting energy expenditure in patients
with cancer (n = 10) but have not been trialled in larger-
scale studies [121]. They are thought to inhibit proteolysis
and lipolysis [122] and have been shown to downregulate
catecholamine-induced catabolism in burns patients [123].
Agents which reduced cytokine levels such as thalidomide
and pentoxifylline have only shown modest or minimal
activity. At RCT, thalidomide has been shown to attenuate
weight loss and lead to improved physical function [35].
Pentoxifylline did not have any clinical beneﬁt. Speciﬁc
antitumour necrosis factor- (TNF-)α agents, etanercept and
inﬂiximab, did not show any positive eﬀect on appetite or
body weight in RCTs [124, 125]. Corticosteroids, although
widely used, have signiﬁcant side eﬀects including protein
breakdown, insulin resistance, water retention, and adrenal
suppression and tend to be used during the preterminal
phaseof patientillness [23,126].Anabolicsteroidderivatives
such as nandrolone and oxandrolone have not been studied
in clinical trials in a cancer cohort. Insulin [27], ATP
infusions [28], and melatonin [41] have produced modest
positive eﬀects in small clinical trials and require further
substantiation.
4.4. Combination Therapy. In unresectable cancer cases,
there is currently no goal standard treatment that can
attenuate catabolism and inﬂammation, stimulate appetite
andintakeandconsequentlypromoteanabolism(speciﬁcally
of lean body mass). A multimodal approach has therefore
been advocated in the treatment of cancer cachexia. Man-
tovani (2010) randomised 332 patients with cancer-related
anorexia/cachexia syndrome tooneofﬁvearmsoftreatment:
(1) medroxyprogesterone 500mg/d or megestrol acetate
320mg/d; (2) oral supplementation with eicosapentaenoic
acid (EPA); (3) L-carnitine 4g/d; (4) thalidomide 200mg/d;
(5) a combination of the above for a total of 4 months [127].
Results showed the superiority of arm 5 over the others
for all primary endpoints. Signiﬁcant improvements were
observed in arm 5 in LBM, fatigue scores, appetite, and total
energy and active energy expenditure with REE decreasing
signiﬁcantly.Toxicitywasnegligibleandcomparablebetween
treatment arms.
4.5. Potential Therapeutic Targets. Due to the lack of clinical
eﬃcacy of agents which seemed promising in the laboratory
setting, ongoing research has continued to explore new
therapeutic targets and to develop new agents. Much of this
has focussed on manipulation of the melanocortin system of
appetite regulation [128]. Activation of the Melanocortin-4-
receptor (MC4R) in murine models decreases food-seeking
behaviour, increases basal metabolic rate, and decreases
lean body mass [80]. Treatment with a MC4R antago-
nist attenuated these responses [79]. Ghrelin induces the
release of growth hormone, regulates appetite, and has anti-
inﬂammatory properties [129, 130]. Initial human studies in
Phase I open trials have conﬁrmed safety and show some
increase in appetite and body weight [131]. Myostatin is a
growth factor involved in the normal regulation of muscle
mass [132]. Myostatin inhibitors and IL-6 antagonists are
currently at Phase I RCT stage in development [131].
5.Conclusions
A consensus deﬁnition incorporating clinical, functional,
and biochemical parameters is necessary in order to ade-
quately identify and treat patients with cancer cachexia. A
greaterunderstanding ofthe pathophysiology,particularly in
terms of the processes which drive cachexia will lead to new
therapeutic target development. A number of issues remain
to be resolved including whether inﬂammation drives the
process or is a byproduct of the process. Does reversal of
weight loss alone result in improved survival? By improving
cachexia (i.e.,leading to improved physical and physiological
function) in cachexia, can patients become better able to
tolerate anticancer therapies such as chemotherapy?
Composite endpoints which measure clinically relevant
outcomes such as physical activity and quality of life are
requiredinordertobestassesstheimpactofinterventionson
cancer cachexia patients. Objective measures of function (as
represented by physical activity) using advance ambulatory
technology and integrated subjective quality of life parame-
ters are likely to become standard practice in the clinical trial
setting.
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